BL(SZ:002592) Zheng Quan Zhi Xing·2025-06-20 11:17Core Viewpoint - The company announced the progress of litigation related to the transfer of equity in Hainan Hongrun Tianyuan Gene Biotechnology Co., Ltd, indicating that the lawsuit will not adversely affect its current or future profits [1][3]. Group 1: Basic Situation of the Lawsuit - Wuhan Baitai Gene Engineering Co., Ltd and Shanghai Ruian Gene Technology Co., Ltd filed lawsuits against Beijing Hongrun Tianyuan Gene Biotechnology Co., Ltd and Guangxi Wanhou Trading Co., Ltd, claiming that the equity transfer affected their creditor rights [1]. - The Beijing Haidian District People's Court made a first-instance judgment to revoke the equity transfer of 100% of Hainan Hongrun's shares from Beijing Hongrun to Guangxi Wanhou [1]. Group 2: Progress of the Lawsuit - Both parties involved in the lawsuits appealed to the Beijing First Intermediate People's Court after being dissatisfied with the first-instance judgment [2]. - A settlement was reached among the parties during the appeal process, and the plaintiffs applied to withdraw their lawsuits during the second-instance hearing [2]. - The court issued a final ruling to revoke the first-instance judgment and allowed the plaintiffs to withdraw their lawsuits [3]. Group 3: Impact on Company Profits - The settlement and the court's decision to allow the withdrawal of lawsuits indicate that there will be no negative impact on the company's current or future profits [3]. Group 4: Other Litigation Matters - The company and its controlling entities currently have no other significant litigation or arbitration matters that need to be disclosed [3].